Alkermes (ALKS) Non-Current Deferred Tax Liability (2011 - 2026)

Alkermes' (ALKS) quarterly Non-Current Deferred Tax Liability came in at $181.9 million in Q1 2026, up 112893.79% on a QoQ basis from $161000.0 in Q1 2016.

Alkermes (ALKS) Non-Current Deferred Tax Liability (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $181.9 million in Q1 2026.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $181.9 million in Q1 2026; TTM through Mar 2026 was $181.9 million, a N/A change from a year earlier, with the FY2015 full-year figure at $470000.0, down 97.52% from the prior year.
  • Non-Current Deferred Tax Liability for Q1 2026 stood at $181.9 million, up from $161000.0 in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for ALKS reached as high as $181.9 million in Q1 2026 and fell as low as $181.9 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 181.92 Mn
Mar 31, 2026 181.92 Mn
Mar 31, 2016 161,000.00
Mar 31, 2016 161,000.00
Dec 31, 2015 470,000.00
Dec 31, 2015 470,000.00
Sep 30, 2015 6.50 Mn
Sep 30, 2015 6.50 Mn
Jun 30, 2015 12.75 Mn
Jun 30, 2015 12.75 Mn
Mar 31, 2015 16.79 Mn
Mar 31, 2015 16.79 Mn
Dec 31, 2014 18.92 Mn
Dec 31, 2014 18.92 Mn
Sep 30, 2014 21.26 Mn
Sep 30, 2014 21.26 Mn
Jun 30, 2014 26.12 Mn
Jun 30, 2014 26.12 Mn
Mar 31, 2014 25.06 Mn
Mar 31, 2014 25.06 Mn